What is the appropriate treatment for a patient with a serum 25‑hydroxy vitamin D level of 14.2 ng/mL?

Treatment for Vitamin D Level of 14.2 ng/mL

For a vitamin D level of 14.2 ng/mL, treat with 50,000 IU of vitamin D2 or D3 once weekly for 8 weeks, followed by maintenance therapy of 1,500-2,000 IU daily. 111

Treatment Algorithm

Initial Correction Phase (8 weeks)

The Endocrine Society Clinical Practice Guideline provides clear, evidence-based dosing for vitamin D deficiency (defined as 25(OH)D <20 ng/mL, which includes your patient's level of 14.2 ng/mL):

• Standard regimen: 50,000 IU vitamin D2 or D3 once weekly for 8 weeks 111
• Alternative daily dosing: 6,000 IU daily for 8 weeks (equivalent to weekly dosing) 11

Target: Achieve serum 25(OH)D level >30 ng/mL 111

Maintenance Phase (after correction)

Once the target level is reached:

• 1,500-2,000 IU daily of vitamin D2 or D3 111

Special Populations Requiring Higher Doses

Obese Patients

If the patient is obese, double or triple the standard dose (at least 6,000-10,000 IU daily) during the correction phase, followed by maintenance of 3,000-6,000 IU daily 111. Obesity significantly reduces vitamin D bioavailability due to sequestration in adipose tissue.

Malabsorption Syndromes

Patients with celiac disease, Crohn's disease, cystic fibrosis, or other malabsorption conditions require 2-3 times the standard dose (6,000-10,000 IU daily) 111.

Medications Affecting Vitamin D Metabolism

Patients on anticonvulsants, glucocorticoids, or antifungals (ketoconazole) need 2-3 times higher doses (at least 6,000-10,000 IU daily) 111.

Monitoring and Follow-up

• Recheck 25(OH)D level after 8 weeks of treatment to confirm adequate response
• If no increase in 25(OH)D after treatment, evaluate for:
  • Non-compliance (most common)
  • Celiac disease 11
  • Occult cystic fibrosis 11
  • Severe malabsorption

Important Clinical Caveats

Safety Considerations

• The 50,000 IU weekly regimen is safe and well-tolerated with no significant risk of hypercalcemia or toxicity 12
• No routine calcium monitoring is needed in otherwise healthy patients
• Exception: Monitor serum calcium in patients with:
  • Primary hyperparathyroidism 11
  • Granulomatous diseases (sarcoidosis, tuberculosis) 11
  • Lymphoma 11

Vitamin D2 vs D3

Either formulation is acceptable 1. Both are equally effective for correcting deficiency, though some evidence suggests D3 may have slightly longer duration of action.

Alternative Regimens

For nursing home residents or patients with compliance concerns:

• 50,000 IU three times weekly for 4 weeks 12
• 100,000 IU monthly 3 (though less well-studied than weekly dosing)

Why This Approach

The Endocrine Society guideline 111 represents the most authoritative and widely-accepted treatment protocol, published in the Journal of Clinical Endocrinology and Metabolism. The 50,000 IU weekly regimen has been validated in multiple studies and effectively raises 25(OH)D levels from deficient ranges (like 14.2 ng/mL) to sufficient levels (>30 ng/mL) in approximately 8 weeks. This approach balances efficacy with safety and is practical for real-world clinical use.

The maintenance dose of 1,500-2,000 IU daily prevents recurrence of deficiency, as lower doses (800-1,000 IU) are often insufficient to maintain optimal levels long-term 11.